{
  "docId": "019de076-91e2-76fd-b3d2-f30dde172711",
  "docSlug": "0239a71f9c69421092604a0a694fdb09",
  "documentTitle": "AstraZeneca | Investor Conference Presentation Deck | 26 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 26,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "other",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a structured grid to map corporate acquisitions/partnerships to strategic goals and therapeutic areas.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-91e2-76fd-b3d2-f30dde172711/6",
  "deckHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711",
  "deckJsonHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711.json",
  "deckAnchorHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.31
      },
      "kind": "image",
      "text": "Company logos: CinCor, Pfizer, Quell, Cellectis, Eccogene, Icosavax, Gracell",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a42220b-747b-4e42-9143-6ac3ac89dc05",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.92,
        "x": 0.04,
        "y": 0.46
      },
      "kind": "list",
      "text": "Strategic rationales for each deal",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19d5cec7-d9c6-42ce-b049-456735193fc2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.75
      },
      "kind": "list",
      "text": "Disease area labels",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1da12c6-24e7-43e0-86b3-1caa6dd3e12b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.6,
        "x": 0.03,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "1. Icosavax and Gracell acquisitions remains subject to customary closing conditions; all clinical development plans mentioned herein subject to deal closure.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7149de1-5f7f-4b32-871b-3d4427ba6e3d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.94,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "title",
      "text": "Value-enhancing deals enhance disease area leadership and next-wave capabilities",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad1a7460-5b7d-4170-80a0-0dc7071631a0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Strong business development momentum through 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63736950-a75d-43da-929f-947f485994ca",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 4,
      "beatId": "89e38b66-4827-4196-94f1-792b29dc13ee",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Early Struggles",
      "beatSlug": "rags-to-riches-early-struggles",
      "evidence": "The deck highlights AstraZeneca's growth challenges and opportunities.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 4,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "4e7501eb-74e6-4ae7-8a18-04c13b6f5ddc",
      "evidence": "The deck outlines AstraZeneca's growth strategy and supporting data.",
      "position": 0,
      "objective": "How AstraZeneca's growth strategy will drive growth through 2030",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}